[{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"43b49031-7b2f-4fd6-93f2-92e595157a5a","acronym":"IIT2015-18-Mita-MK3475","url":"https://clinicaltrials.gov/study/NCT03025035","created_at":"2021-01-18T14:53:19.998Z","updated_at":"2025-02-25T16:05:43.824Z","phase":"Phase 2","brief_title":"Pembrolizumab in Combination with Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer","source_id_and_acronym":"NCT03025035 - IIT2015-18-Mita-MK3475","lead_sponsor":"Yuan Yuan","biomarkers":" BRCA • CDK6","pipe":" | ","alterations":" HER-2 positive • HR positive • BRCA mutation","tags":["BRCA • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lynparza (olaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/10/2017","start_date":" 09/10/2017","primary_txt":" Primary completion: 10/08/2024","primary_completion_date":" 10/08/2024","study_txt":" Completion: 08/08/2026","study_completion_date":" 08/08/2026","last_update_posted":"2024-12-11"},{"id":"676dfb5a-6692-4639-bd2b-6232077e3caa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02896335","created_at":"2021-01-18T14:12:49.075Z","updated_at":"2025-02-25T16:05:12.381Z","phase":"Phase 2","brief_title":"Palbociclib and Pembrolizumab in Central Nervous System Metastases","source_id_and_acronym":"NCT02896335","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" CCNE1 amplification • CCND1 amplification • CDK4 amplification","tags":["CDKN2A • CCND1 • CCNE1 • CDK4 • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCNE1 amplification • CCND1 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ibrance (palbociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/02/2017","start_date":" 02/02/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-11-21"},{"id":"a896ec8e-9825-4531-a478-c93b653bba25","acronym":"","url":"https://clinicaltrials.gov/study/NCT02057133","created_at":"2021-01-17T17:28:58.622Z","updated_at":"2025-02-25T14:00:24.405Z","phase":"Phase 1","brief_title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","source_id_and_acronym":"NCT02057133","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2 • CDK4 • CDK6","pipe":" | ","alterations":" HR positive • HER-2 negative • EGFR positive","tags":["HER-2 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • everolimus • tamoxifen • Perjeta (pertuzumab) • Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole • exemestane • samotolisib (LY3023414) • loperamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 03/10/2014","start_date":" 03/10/2014","primary_txt":" Primary completion: 03/15/2021","primary_completion_date":" 03/15/2021","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"cdc94ba9-685c-46f1-866d-1a45145be2cd","acronym":"eMonarcHER","url":"https://clinicaltrials.gov/study/NCT04752332","created_at":"2022-01-12T18:08:41.034Z","updated_at":"2024-07-02T16:35:00.441Z","phase":"Phase 3","brief_title":"A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer","source_id_and_acronym":"NCT04752332 - eMonarcHER","lead_sponsor":"Eli Lilly and Company","biomarkers":" CDK6","pipe":"","alterations":" ","tags":["CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2450","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-05-29"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"cb41102b-0fb2-48d9-9bc0-4853a675d51c","acronym":"ELUCIDATE","url":"https://clinicaltrials.gov/study/NCT05985655","created_at":"2023-08-14T16:10:12.231Z","updated_at":"2024-07-02T16:35:16.495Z","phase":"Phase 1/2","brief_title":"Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05985655 - ELUCIDATE","lead_sponsor":"Exscientia AI Limited","biomarkers":" HER-2 • CDK6 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CDK6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e REC-617"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-03-05"},{"id":"3fe15ba6-c8bd-43a0-9070-1c6451e7aaf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03310879","created_at":"2021-01-18T16:21:04.198Z","updated_at":"2024-07-02T16:35:20.810Z","phase":"Phase 2","brief_title":"Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6","source_id_and_acronym":"NCT03310879","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 11/21/2017","start_date":" 11/21/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-02-06"},{"id":"266a2712-9c1f-4bc2-b88c-002f9d951d7d","acronym":"GOG-3039","url":"https://clinicaltrials.gov/study/NCT04393285","created_at":"2023-12-13T16:16:37.842Z","updated_at":"2024-07-02T16:35:26.346Z","phase":"Phase 2","brief_title":"Abemaciclib and Letrozole to Treat Endometrial Cancer","source_id_and_acronym":"NCT04393285 - GOG-3039","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20","pipe":" | ","alterations":" CCND1 expression • CCND1 mutation","tags":["ER • CDKN2A • RB1 • CD8 • PD-1 • CCND1 • CCNE1 • CDK4 • CTLA4 • IL2RA • CDK6 • PTPRC • FOXP3 • CCNE2 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 expression • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 10/10/2020","start_date":" 10/10/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-13"},{"id":"2a514802-0bd5-42d1-abc9-294d1a4f3448","acronym":"","url":"https://clinicaltrials.gov/study/NCT06133088","created_at":"2023-11-15T19:16:06.349Z","updated_at":"2024-07-02T16:35:29.099Z","phase":"Phase 2","brief_title":"Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.","source_id_and_acronym":"NCT06133088","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" CDK6 • LRPPRC","pipe":"","alterations":" ","tags":["CDK6 • LRPPRC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • AiRuiKang (dalpiciclib) • R-(-)-gossypol (AT 101)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-11-15"},{"id":"b39d6f05-f231-4745-aadd-73899fae2d7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04594005","created_at":"2021-01-19T20:29:03.455Z","updated_at":"2024-07-02T16:35:34.460Z","phase":"Phase 1/2","brief_title":"CDK4/6 Tumor, Abemaciclib, Paclitaxel","source_id_and_acronym":"NCT04594005","lead_sponsor":"Yonsei University","biomarkers":" CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 amplification • CDK4 amplification • CCND1 mutation","tags":["CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 amplification • CDK4 amplification • CCND1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/25/2021","start_date":" 02/25/2021","primary_txt":" Primary completion: 08/10/2024","primary_completion_date":" 08/10/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2023-10-06"},{"id":"43035839-3bf9-43e5-bbd5-afd4d6d1337c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02981940","created_at":"2021-01-18T14:40:08.944Z","updated_at":"2024-07-02T16:35:41.812Z","phase":"Phase 2","brief_title":"A Study of Abemaciclib in Recurrent Glioblastoma","source_id_and_acronym":"NCT02981940","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CDKN2A • RB1 • CDK4 • CDKN2B • CDK6","pipe":" | ","alterations":" CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type","tags":["CDKN2A • RB1 • CDK4 • CDKN2B • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A deletion • CDK4 amplification • IDH wild-type • RB1 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 02/09/2017","start_date":" 02/09/2017","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-27"},{"id":"4c36bc05-4f8b-4445-89c4-c81896c29440","acronym":"BioPER","url":"https://clinicaltrials.gov/study/NCT03184090","created_at":"2021-01-18T15:42:02.729Z","updated_at":"2024-07-02T16:36:08.551Z","phase":"Phase 2","brief_title":"Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC","source_id_and_acronym":"NCT03184090 - BioPER","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • HIF1A • CDK6 • CDKN1A • SKP2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2 • ER • PGR • HIF1A • CDK6 • CDKN1A • SKP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • tamoxifen • fulvestrant • exemestane"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 06/28/2017","start_date":" 06/28/2017","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 10/27/2020","study_completion_date":" 10/27/2020","last_update_posted":"2022-06-21"},{"id":"cdf6c9e0-2e9e-4ffb-b0ae-b679fa7d891e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792256","created_at":"2021-01-18T18:44:58.864Z","updated_at":"2024-07-02T16:36:16.243Z","phase":"Phase 1","brief_title":"Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)","source_id_and_acronym":"NCT03792256","lead_sponsor":"Children's Oncology Group","biomarkers":" RB1 • CD8 • CDK4 • CDK6 • CD4 • CCND3","pipe":" | ","alterations":" RB1 expression • CDK6 expression • CDKN1B expression","tags":["RB1 • CD8 • CDK4 • CDK6 • CD4 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 expression • CDK6 expression • CDKN1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • cytarabine • doxorubicin hydrochloride • vincristine • prednisone • Oncaspar liquid (pegaspargase) • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-03-02"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"ac5f2287-70c4-478b-b6d5-985e51adf32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03201913","created_at":"2021-02-11T09:05:51.453Z","updated_at":"2024-07-02T16:36:42.146Z","phase":"Phase 1","brief_title":"Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy","source_id_and_acronym":"NCT03201913","lead_sponsor":"TTC Oncology, LLC","biomarkers":" CDK6","pipe":"","alterations":" ","tags":["CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TTC-352"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 12/11/2017","start_date":" 12/11/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 04/30/2020","study_completion_date":" 04/30/2020","last_update_posted":"2020-08-11"},{"id":"de3ecf6b-3b4c-409e-bd4d-5f880ce8753e","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT02187783","created_at":"2021-01-18T10:12:32.699Z","updated_at":"2024-07-02T16:36:57.957Z","phase":"Phase 2","brief_title":"LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)","source_id_and_acronym":"NCT02187783 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDKN2A • CCND1 • CDK4 • CDK6 • CCND3","pipe":" | ","alterations":" CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification","tags":["CDKN2A • CCND1 • CDK4 • CDK6 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A mutation • CCND1 amplification • CDK4 amplification • CCND1 mutation • CDK4 mutation • CDK6 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 08/25/2014","start_date":" 08/25/2014","primary_txt":" Primary completion: 01/17/2018","primary_completion_date":" 01/17/2018","study_txt":" Completion: 01/17/2018","study_completion_date":" 01/17/2018","last_update_posted":"2019-07-18"},{"id":"53957826-5214-47a6-a297-47b804f3dba0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02310243","created_at":"2021-01-18T10:56:16.385Z","updated_at":"2024-07-02T16:37:00.586Z","phase":"Phase 1/2","brief_title":"Study of Palbociclib in MLL-rearranged Acute Leukemias","source_id_and_acronym":"NCT02310243","lead_sponsor":"University of Ulm","biomarkers":" KMT2A • CDK6","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["KMT2A • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Unknown status","enrollment":" Enrollment 50","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2019-04-16"},{"id":"6fb2f996-40be-410d-8d49-338dede4d17b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02345824","created_at":"2021-01-18T11:09:22.531Z","updated_at":"2025-02-25T15:42:14.957Z","phase":"Phase 1","brief_title":"Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma","source_id_and_acronym":"NCT02345824","lead_sponsor":"University of Virginia","biomarkers":" RB1 • CDK4 • CDK6","pipe":"","alterations":" ","tags":["RB1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib)"],"overall_status":"Unknown status","enrollment":" Enrollment 3","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2018-06-07"},{"id":"e8456c97-4ee4-47f4-89b8-43e1a9f2db63","acronym":"PALBONET","url":"https://clinicaltrials.gov/study/NCT02806648","created_at":"2021-01-18T13:45:55.470Z","updated_at":"2024-07-02T16:37:14.609Z","phase":"Phase 2","brief_title":"A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)","source_id_and_acronym":"NCT02806648 - PALBONET","lead_sponsor":"Grupo Espanol de Tumores Neuroendocrinos","biomarkers":" RB1 • CCND1 • CDK4 • CDK6","pipe":" | ","alterations":" CCND1 overexpression • CDK4 overexpression • RB1 overexpression • CDK6 expression","tags":["RB1 • CCND1 • CDK4 • CDK6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CCND1 overexpression • CDK4 overexpression • RB1 overexpression • CDK6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 07/01/2017","primary_completion_date":" 07/01/2017","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2018-01-23"}]